Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Fortress Biotech, Inc. (FBIO)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $61.2M | $55.1M | $59.7M | $71.0M | $63.1M | $44.5M | $34.9M | $23.4M | $15.5M | $16.5M | $863,000 | $0 | $0 | — | — | — | — | — | — |
| Research & development | $11.9M | $56.6M | $101.7M | $134.2M | $113.2M | $61.3M | $6.1M | $83.3M | $48.3M | $35.1M | $29.8M | $10.2M | $25.7M | $17.5M | $8.6M | $8.3M | $2.3M | — | — |
| Operating expenses | — | — | — | — | — | — | — | $146.9M | $107.0M | $82.2M | $51.4M | $20.7M | $35.8M | — | — | — | — | — | — |
| Operating income | −$70.2M | −$110.4M | −$142.3M | −$203.6M | −$188.5M | −$94.3M | −$110.8M | −$120.0M | −$89.8M | −$65.7M | −$50.5M | −$20.7M | −$35.8M | −$27.2M | −$35.0M | −$9.2M | −$2.6M | — | — |
| EBITDAderived | −$65.6M | −$105.9M | −$136.3M | −$196.2M | — | −$90.6M | −$107.7M | — | −$88.6M | −$64.8M | −$50.5M | −$20.6M | −$35.8M | — | — | — | — | — | — |
| Net income | $6.8M | −$46.0M | −$60.6M | −$86.6M | −$64.7M | −$46.5M | −$40.0M | −$84.1M | −$66.9M | −$55.1M | −$48.4M | −$20.4M | −$37.2M | −$27.6M | −$36.4M | −$10.0M | −$3.7M | −$3.8M | −$2.6M |
| Basic EPSper diluted share | -$0.07 | -$2.69 | -$8.47 | -$15.97 | -$0.79 | -$0.65 | -$0.73 | -$1.94 | -$1.61 | -$1.38 | -$1.24 | -$0.56 | -$1.22 | -$1.27 | -$5.51 | -$2.24 | -$1.01 | — | — |
| Diluted EPSper diluted share | -$0.07 | -$2.69 | -$8.47 | -$15.97 | -$0.79 | -$0.65 | -$0.73 | -$1.94 | -$1.61 | -$1.38 | -$1.24 | -$0.56 | -$1.22 | -$1.27 | -$5.51 | -$2.24 | -$1.01 | — | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Sep 23, 2024Form 4 | ROSENWALD LINDSAY A MDPRESIDENT, CEO & CHAIRMAN | BuyCommon stock, par value $0.001 | 763.4K | $1.84 | $1.40M | 3.66M |
| Sep 23, 2024Form 4 | ROSENWALD LINDSAY A MDPRESIDENT, CEO & CHAIRMAN | BuyWarrants to Purchase Common Stock · derivative | 763.4K | $0.13 | $99.2K | 763.4K |
| Jul 11, 2024Form 4 | ROSENWALD LINDSAY A MDPresident, CEO & Chairman | BuySERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | 5.0K | $7.48 | $37.4K | 127.5K |
| Jul 10, 2024Form 4 | Jin DavidChief Financial Officer | BuySERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | 500 | $7.50 | $3.8K | 500 |
| Jul 9, 2024Form 4 | ROSENWALD LINDSAY A MDPresident, CEO & Chairman | BuySERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | 5.0K | $7.39 | $37.0K | 122.5K |